GDTC CytoMed Therapeutics
- 2.255
- +0.185+8.94%
CytoMed Therapeutics News
CytoMed Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
CytoMed Therapeutics | 20-F: Registration statement / Annual report / Transition report
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-mDR Limited(11.59%)
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CytoMed Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Zeng Jieming(5.11%)
CytoMed Therapeutics | 20-F: Registration statement / Annual report / Transition report
CytoMed Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-mDR Limited(11.60%)
CytoMed Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Glorious Finance Limited(42.54%),Choo Chee Kong(28.86%)
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
CytoMed Therapeutics | 424B4: Prospectus
CytoMed Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Loh Yuin Han
CytoMed Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Leong Mark Kei Wei
CytoMed Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Zeng Jieming
Analysis
Price Target
No Data
